country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-13976A

Copy Link Print Information

PRL-8-53

PRL-8-53 is an orally active, blood-brain barrier-permeable benzoate derivative with potent spasmolytic activity and central nervous system regulatory activity. PRL-8-53 acts on dopamine, serotonin and cholinergic-related targets, enhances dopamine activity, partially inhibits serotonin function and elicits cholinergic responses, thereby maintaining neurotransmitter balance in the central nervous system. PRL-8-53 improves learning ability, short-term memory and long-term memory in animals. PRL-8-53 can be used in central nervous system-related research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 51352-87-5
Formel: C₁₈H₂₂ClNO₂
Molecular Weight:319.83

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (266 KB)

PRL-8-53 Chemical Structure

CAS. Nr.: 51352-87-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

PRL-8-53 modulates dopamine, serotonin and cholinergic targets, potentiates dopamine activity, partially inhibits serotonin function and triggers cholinergic responses in experimental animals^[1]^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PRL-8-53 (p.o.) exhibits low oral toxicity in mice and depresses motor activity with an ED₅₀ of 160 mg/kg, without inducing stereotypic behavior at doses up to 200 mg/kg^[1].
PRL-8-53 does not alter d-amphetamine stimulant effects or avoidance rate in rats at tested doses, reverses reserpine-induced catatonia and ptosis, and does not induce stereotypic behavior at doses up to 200 mg/kg^[1].
PRL-8-53 does not significantly alter blood pressure in normotensive dogs at doses up to 8 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 51352-87-5
Molecular Weight 319.83
Formel C₁₈H₂₂ClNO₂
SMILES

O=C(C1=CC=CC(CCN(CC2=CC=CC=C2)C)=C1)OC.Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (266 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hansl NR, et al. PRL-8-53: enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent. Psychopharmacology (Berl). 1978;56(3):249-253. [Content Brief]

[2]. Hansl NR. A novel spasmolytic and CNS active agent 3-(2-benzylmethylaminoethyl) benzoic acid methyl ester hydrochloride. Experientia. 1974 Mar 01;30:271-272.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen